Spots Global Cancer Trial Database for gsk2118436
Every month we try and update this database with for gsk2118436 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors | NCT01231594 | Cancer | GSK2118436 GSK1120212 Other approved ... | 18 Years - | Novartis | |
| A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors | NCT01738451 | Cancer | GSK2118436 75 m... Placebo | 18 Years - | GlaxoSmithKline | |
| A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors | NCT01582997 | Cancer | GSK2118436 | 20 Years - | GlaxoSmithKline | |
| An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors | NCT01262963 | Cancer | GSK2118436 | 18 Years - | GlaxoSmithKline | |
| An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors | NCT01262963 | Cancer | GSK2118436 | 18 Years - | GlaxoSmithKline | |
| A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma | NCT01227889 | Cancer | GSK2118436 Dacarbazine (DT... | 18 Years - | GlaxoSmithKline | |
| A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma | NCT01227889 | Cancer | GSK2118436 Dacarbazine (DT... | 18 Years - | GlaxoSmithKline | |
| A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors | NCT00880321 | Cancer | GSK2118436 GSK2118436 Midazolam | 18 Years - | GlaxoSmithKline | |
| Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 | NCT01534897 | Papillary Thyro... | GSK2118436 | 18 Years - | Massachusetts General Hospital | |
| An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor | NCT01619774 | Melanoma | GSK2118436 GSK1120212 | 16 Years - | M.D. Anderson Cancer Center | |
| A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors | NCT01340846 | Cancer | Warfarin Ketoconazole Gemfibrozil GSK2118436 150m... GSK2118436 75mg | 18 Years - | GlaxoSmithKline | |
| An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor | NCT01231568 | Cancer | Regimen A Regimen B Regimen C Regimen D | 18 Years - | GlaxoSmithKline | |
| Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors | NCT01340833 | Cancer | GSK2118436 | 18 Years - | GlaxoSmithKline | |
| Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors | NCT01340833 | Cancer | GSK2118436 | 18 Years - | GlaxoSmithKline | |
| A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain | NCT01266967 | Melanoma and Br... | GSK2118436 | 18 Years - | GlaxoSmithKline | |
| Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. | NCT01336634 | Cancer | Dabrafenib Trametinib | 18 Years - | Novartis | |
| Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | NCT01072175 | Cancer | GSK2118436 GSK1120212 | 18 Years - | Novartis | |
| Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites | NCT01978236 | Melanoma and Br... | Dabrafenib 150 ... Trametinib 2.0 ... | 18 Years - | GlaxoSmithKline | |
| Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. | NCT01336634 | Cancer | Dabrafenib Trametinib | 18 Years - | Novartis | |
| Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites | NCT01978236 | Melanoma and Br... | Dabrafenib 150 ... Trametinib 2.0 ... | 18 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
